Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Meijin Ren
Observed name:
M. Ren
Institutions:
Nanjing University of Chinese Medicine,
Nanjing Drum Tower Hospital
Observed institutions:
Nanjing University of Chinese Medicine,
Nanjing Drum Tower Hospital
ORCID:
0009-0004-0637-8773
Observed ORCID:
0009-0004-0637-8773
OpenAlex ID:
A5108617620
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
2024
·
Wen Hao
, Wenjing Liu
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
12
PDF
Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy
2024
·
Wen Hao
, Ruimin Chang
, et al.
·
Frontiers in Immunology
·
9
PDF
The clinical significance of hyperthermic intraperitoneal chemotherapy combined with PD-1 inhibitor and systemic chemotherapy for advanced gastric cancer patients with peritoneal metastasis: a single-center retrospective study
2026
·
Meijin Ren
, Jiaqi Xie
, et al.
·
Frontiers in Oncology
·
3
PDF
Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials.
2011
·
D. S. Hong
, D. S. Boss
, et al.
·
Journal of Clinical Oncology
·
2
Rechallenge With Immune Checkpoint Inhibitors in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2026
·
M. Ren
, Y. Wang
, et al.
·
Clinical Oncology
·
1
PDF
Prognostic impact of baseline blood biomarkers in SCLC first-line treatment
2026
·
Yibing Wang
, Meijin Ren
, et al.
·
Therapeutic Advances in Medical Oncology
Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080.
2011
·
J. J. Nemunaitis
, D. S. Hong
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
7
Citation count:
27
H-index:
3
I10-index:
1
Year
Topic
Type